Rebecca Smith-Bindman, a professor at the University of California-San Francisco medical school, has spent well over a decade researching the disquieting risk that one of modern medicine’s most valuable tools, computerized tomography scans, can sometimes cause cancer. Smith-Bindman and like-minded colleagues have long pushed for federal policies aimed at improving safety for patients undergoing CT…
Phase 3 results for the Novartis malaria drug “GanLum” show it was comparable to the standard of care and led to cure rates that top the threshold recommended by the World Health Organization. If approved, this new combination drug would become the first novel malaria therapy in more than 25 years. The post Novel Novartis…
El triunfo electoral del ex presidente Donald Trump y su regreso a la Casa Blanca probablemente traerán cambios que reducirían los programas nacionales de salud públicos, aumentando la tasa de personas sin seguro e imponiendo nuevas barreras al aborto y otros servicios de salud reproductiva. Las repercusiones se sentirán mucho más allá de Washington, DC,…
Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement. The post Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for…
National Cancer Institute funding to help establish the Virginia Advancing Cancer Control Equity Research Through Transformative Solutions (VA-ACCERT) Center
Iambic’s latest financing follows the presentation of data for its breast cancer drug during the recent European Society of Medical Oncology conference. Our financing roundup includes capital raised by startups developing novel therapies immunology, metabolic disorders, genetic diseases, and more. The post Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs appeared first…
In October, Stanford University professor Jay Bhattacharya hosted a conference on the lessons of covid-19 in order “to do better in the next pandemic.” He invited scholars, journalists, and policy wonks who, like him, have criticized the U.S. management of the crisis as overly draconian. Bhattacharya also invited public health authorities who had considered his…
What if these two worlds weren’t at odds? What if they were two parts of the same story, waiting to be brought together for the benefit of all? The post Bridging the Gap Between Herbal Wisdom and Scientific Research appeared first on MedCity News.
By SAURABH JHA Early on in the COVID-19 pandemic a seroprevalence study from Santa Clara indicated that the viral spread was far greater than was believed. The study suggested that the infection fatality rate (IFR) was much lower than the case fatality rate and perhaps even lower than the suspected IFR. The researchers estimated that…